Relay Therapeutics
A new breed of company at the intersection of computation and biotechnology that is committed to creating medicines that will have a transformative impact on patients.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 20.6x EV/Revenue -32.5x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $200m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (96 %) | (54 %) | 1750 % | (61 %) | 35 % | 47 % | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2949 %) | (23362 %) | (1490 %) | (3931 %) | (2319 %) | (1619 %) | (1446 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (12013 %) | (21036 %) | (1339 %) | (3375 %) | (2102 %) | (1446 %) | (1334 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 5700 % | 17839 % | 1292 % | 3189 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Relay Therapeutics is a pioneering biotech company focused on revolutionizing drug discovery by placing protein motion at the core of its research. The company operates primarily in the pharmaceutical and biotechnology markets, targeting complex diseases that have been challenging to treat with existing methods. Relay Therapeutics serves a diverse range of clients, including patients, healthcare providers, and pharmaceutical companies.
The company's business model revolves around its innovative Dynamo™ platform, which combines cutting-edge experimental and computational techniques to identify and develop new therapeutic candidates. This platform allows Relay to target proteins that have been difficult or impossible to drug in the past, thereby expanding the possibilities for effective treatments. Relay Therapeutics is particularly focused on precision oncology (cancer treatment tailored to individual genetic profiles) and genetic diseases.
Relay makes money through a combination of licensing agreements, collaborations, and the development of its own drug pipeline. For instance, the company has entered into a worldwide license and collaboration agreement with Genentech, a major player in the biotech industry. These partnerships not only provide immediate revenue but also validate the potential of Relay's technology and approach.
The company's ultimate goal is to bring life-changing medicines to patients, and it is actively involved in clinical trials to test the efficacy and safety of its drug candidates. Relay's team is described as highly integrated, collaborative, and entrepreneurial, which is essential for driving innovation in such a complex and competitive field.
Keywords: biotech, drug discovery, protein motion, precision oncology, genetic diseases, Dynamo platform, clinical trials, licensing, collaboration, innovation.